FDA's oncology adcomm to review PI3K inhibitors in blood cancers in April

An attractive cancer target is going to be in the hot seat at an FDA advisory committee on April 21.

The FDA’s oncologic drugs advisory committee, or ODAC, will specifically discuss a particular class of cancer drugs, known as phosphatidylinositol-3-kinase, or PI3K, inhibitors, that are currently under development in patients with hematologic malignancies, or blood cancers.